Novartis pitches discounts on pricey gene therapy for SMA
Source: Reuters Novartis AG is offering price discounts in negotiations with U.S. health insurers on its gene therapy for spinal muscular atrophy (SMA), a treatment that could cost more than a million dollars, but the gesture comes with strings attached. The Swiss drugmaker wants insurers to commit to coverage for patients identified with the rare